Functionalized Chitosan Chelation for Local Metal Dysregulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases characterized by local inflammation and metal dysregulation, such as neurodegenerative diseases and ocular diseases, are inadequate due to systemic side effects and inefficiencies, necessitating a safe and localized treatment to restore metal homeostasis.
Innovation Solution
A functionalized chitosan with a molecular weight between 100 kDa and 1000 kDa, containing chelating agents and linkers, is used to selectively target and chelate metals locally, formulated as an injectable solution for administration in specific body cavities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic chelation therapy is used to treat metal dysregulation, then metal homeostasis can be restored, but severe systemic side effects occur including liver or kidney damage and irreversible neurological damage
Solution Approach 1:
The patent applies local quality by developing a chitosan derivative with specific molecular characteristics (weight average molecular mass between 100 kDa and 1000 kDa, specific degree of deacetylation) that enables localized action at the site of metal accumulation. The chitosan derivative is administered locally (e.g., intravitreal injection for ocular diseases, intraperitoneal injection for peritoneal inflammation) rather than systemically, concentrating the chelating effect where needed while avoiding widespread tissue exposure and associated toxicity.
Solution Approach 2:
The patent utilizes parameter changes by carefully controlling the molecular weight (100-1000 kDa range), degree of deacetylation (20-80%), and chelating agent composition to optimize the balance between chelation efficacy and biocompatibility. These parameter modifications enable the chitosan derivative to achieve effective metal chelation while minimizing systemic absorption and associated harmful effects.
2Reliability
If high-dose chelating agents are used to achieve effective metal chelation, then metal homeostasis is restored, but cytotoxicity and severe side effects increase
Solution Approach 1:
The patent employs composite materials by combining chitosan polymer with specific chelating agents (such as DFO, DOTAGA, or other metal-chelating moieties) to create a conjugated chitosan derivative. This composite structure leverages the biocompatibility and metabolic safety of chitosan while incorporating the high-affinity metal chelation capability of the chelating agents, achieving effective chelation with reduced cytotoxicity compared to conventional high-dose chelating agents alone.
3Adaptability or versatility
If conventional chelation therapy is administered systemically, then metal dysregulation can be addressed, but insufficient benefit to risk ratio is achieved for local inflammation conditions
Solution Approach 1:
The patent resolves this contradiction by transitioning from systemic to local administration. The chitosan derivative is designed and administered specifically for local use at the site of metal accumulation and inflammation (e.g., eye, peritoneum, joint space), providing concentrated chelation therapy where needed while avoiding the risks associated with systemic distribution. This localizes the benefit-risk ratio favorably by limiting exposure to healthy tissues.
4Reliability
If standard chelation therapy is used for local inflammation, then metal chelation occurs, but treatment is insufficient due to lack of localization
Solution Approach 1:
The patent achieves localization precision by formulating the chitosan derivative for specific routes of administration targeting particular body cavities or tissues. The molecular size and charge characteristics of the chitosan derivative facilitate penetration and retention at the injection site, ensuring that metal chelation occurs primarily where the agent is administered rather than systemically throughout the body.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The functionalized chitosan effectively reduces local inflammation and oxidative stress by restoring metal homeostasis without systemic side effects, providing a safer and more effective treatment option.
Implementation Method 1
A functionalized chitosan with a molecular weight between 100 kDa and 1000 kDa, containing chelating agents and linkers, is used to selectively target and chelate metals locally
Implementation Method 2
The functionalized chitosan effectively reduces local inflammation and oxidative stress by restoring metal homeostasis
Data Source
AI summary
The present disclosure relates to a functionalized statistic chitosan of weight average molecular mass between 100 kDa and 1000 kDa and of formula (I):whereineach Rc is independently a moiety comprising a chelating agent,each Z is independently a linker which is a single bond or a hydrocarbon chain containing between 1 and 12 carbon atoms, said hydrocarbon chain is linear or branched and optionally contains one or more unsaturations and one or more heteroatoms,x is between 0.005 and 0.7, preferably between 0.05 and 0.7,y is between 0.01 and 0.7, preferably between 0.05 and 0.2,the ratio y/x being greater than or equal to 0.05, preferably greater than or equal to 0.15, andthe sum x+y being greater than or equal to 0.15, for use in the treatment of diseases characterized by local inflammation induced by and/or inducing a deregulation of metal homeostasis and increased oxidative stress, in a subject in need thereof.